<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03491462</url>
  </required_header>
  <id_info>
    <org_study_id>ORARIALS-01</org_study_id>
    <nct_id>NCT03491462</nct_id>
  </id_info>
  <brief_title>Arimoclomol in Amyotropic Lateral Sclerosis</brief_title>
  <official_title>A Phase 3, Randomised, Placebo-Controlled Trial of Arimoclomol in Amyotropic Lateral Sclerosis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Orphazyme</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Orphazyme</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      A multicenter, randomized, double-blind, placebo-controlled, parallel group trial to evaluate
      the efficacy and safety of arimoclomol in amyotropic lateral sclerosis (ALS)
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Screening of up to 4 weeks Treatment of up to 76 weeks
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">May 31, 2018</start_date>
  <completion_date type="Anticipated">January 14, 2021</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2020</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>placebo-controlled, parallel group</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
    <masking_description>Double-blind</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Combined Assessment of Function and Survival (CAFS)</measure>
    <time_frame>over 76 Weeks</time_frame>
    <description>Time to event (Permanent assisted ventilation, tracheostomy or death) is combined with ALSFRS-R score (12 functions on a 5-point ordinal rating scale with maximum score of 48) to create a nonparametric rank analysis of covariance</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Time to permanent assisted ventilation (PAV)/tracheostomy/death</measure>
    <time_frame>over 76 weeks</time_frame>
    <description>time from baseline to event</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>ALS Function Rating Scale, Revised (ALSFRS-R)</measure>
    <time_frame>over 76 weeks</time_frame>
    <description>measure of patient function</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Slow Vital Capacity (SVC)</measure>
    <time_frame>over 76 weeks</time_frame>
    <description>measurement for the quality of breathing</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">231</enrollment>
  <condition>Amyotrophic Lateral Sclerosis</condition>
  <arm_group>
    <arm_group_label>Arimoclomol</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Arimoclomol, capsule, 200mg x 2, three times daily, 76 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo matching to experimental Arm</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Arimoclomol</intervention_name>
    <description>Active treatment</description>
    <arm_group_label>Arimoclomol</arm_group_label>
    <other_name>Arimoclomol citrate</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo oral capsule</intervention_name>
    <description>Matching placebo capsule</description>
    <arm_group_label>Placebo</arm_group_label>
    <other_name>Placebo</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Subject meets revised El Escorial criteria for clinically possible, clinically
             probable / Clinically probable ALS laboratory-supported or clinically definite ALS, or
             familial ALS

          -  18 months or less since first appearance of weakness

          -  ALSFRS-R equal to or above 35 and erect SVC% predicted equal to or above 80% at
             screening

        Exclusion Criteria:

          -  Tracheostomy or use of non-invasive ventilation for more than 2 hours during waking
             hours at the time of screening or baseline

          -  pregnant or breast-feeding

          -  current or anticipated use of diaphragmatic pacing

          -  Any other relevant medically significant condition which could present risk to the
             subject or interfere with the assessment of safety or has an increased risk of causing
             death during the trial
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Michael Benatar, MD PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Miami</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Clinical Project Manager</last_name>
    <phone>+45 53 70 68 09</phone>
    <email>rbe@orphazyme.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Richard M Bennett, BSc</last_name>
    <phone>+45 53 70 68 09</phone>
    <email>rbe@orphazyme.com</email>
  </overall_contact_backup>
  <verification_date>April 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 27, 2018</study_first_submitted>
  <study_first_submitted_qc>April 6, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">April 9, 2018</study_first_posted>
  <last_update_submitted>April 6, 2018</last_update_submitted>
  <last_update_submitted_qc>April 6, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">April 9, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>arimoclomol</keyword>
  <keyword>ALS</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sclerosis</mesh_term>
    <mesh_term>Motor Neuron Disease</mesh_term>
    <mesh_term>Amyotrophic Lateral Sclerosis</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

